新华制药(000756) - 2021 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2021 was CNY 1,768,119,883.04, representing a 3.64% increase compared to CNY 1,705,982,914.01 in the same period last year[7] - The net profit attributable to shareholders for Q1 2021 was CNY 100,276,326.14, a 16.21% increase from CNY 86,286,544.27 year-on-year[7] - The net profit after deducting non-recurring gains and losses was CNY 96,454,109.91, up 22.80% from CNY 78,547,417.73 in the previous year[7] - The total operating income for Q1 2021 was CNY 949,499,126.18, a decrease of 4.02% from CNY 989,274,388.58 in the same period last year[45] - The net profit for Q1 2021 reached CNY 105,675,789.00, representing an increase of 13.00% compared to CNY 93,483,236.19 in Q1 2020[43] - The company achieved a net profit attributable to shareholders of CNY 100,276,326.14, up from CNY 86,286,544.27, marking a growth of 15.93%[43] - The total profit for Q1 2021 was CNY 129,187,925.43, an increase of 12.66% from CNY 114,647,500.02 in Q1 2020[1] Cash Flow - The company's cash flow from operating activities was CNY 89,368,875.29, down 14.83% from CNY 104,929,221.85 in the same period last year[7] - Net cash inflow from financing activities in Q1 2021 was RMB 28,806,822.77, a decrease of 95.15% compared to the same period last year, mainly due to a loan of RMB 600,000,000.00 obtained from the controlling shareholder in the previous year[16] - Operating cash inflow totaled CNY 1,328,906,874.60, a slight increase from CNY 1,318,507,689.52 in the previous period[49] - Net cash outflow from operating activities was CNY 1,239,537,999.31, compared to CNY 1,213,578,467.67 in the prior period[50] - Cash and cash equivalents at the end of the period amounted to CNY 788,049,366.09, a decrease from CNY 1,225,308,621.24 in the previous period[51] - Net cash flow from financing activities was CNY 28,806,822.77, significantly lower than CNY 593,389,904.31 in the same period last year[51] - Cash inflow from financing activities totaled CNY 414,967,280.00, down from CNY 620,000,000.00 in the previous year[50] - The net increase in cash and cash equivalents was CNY 65,486,139.53, compared to CNY 647,684,027.87 in the previous year[51] - The company reported a decrease in cash flow from operating activities net amounting to CNY 6,698,332.02, down from CNY 113,856,792.83 year-over-year[52] Assets and Liabilities - Total assets at the end of the reporting period were CNY 7,279,400,356.04, an increase of 2.63% from CNY 7,092,952,190.04 at the end of the previous year[7] - The net assets attributable to shareholders increased by 4.21% to CNY 3,359,487,089.39 from CNY 3,223,793,819.25 at the end of the previous year[7] - Total liabilities increased to CNY 3,744,102,094.08 in Q1 2021 from CNY 3,701,662,448.12 in Q4 2020, reflecting a rise of approximately 1.14%[36] - The total non-current liabilities increased to CNY 1,593,939,088.94 from CNY 1,320,623,205.53, indicating a rise of about 20.6%[36] - Short-term borrowings increased by 54.06% to CNY 308,774,051.97 compared to the beginning of the year, while long-term borrowings rose by 55.89% to CNY 721,352,672.51[15] Accounts Receivable and Inventory - Accounts receivable as of March 31, 2021, were CNY 707,881,350.32, up 86.33% compared to the beginning of the year, mainly due to expanded sales scale[15] - Accounts receivable increased significantly to CNY 514,069,169.07 from CNY 297,382,259.35, representing a growth of about 73%[37] - Inventory decreased to RMB 914,867,443.33 as of March 31, 2021, down from RMB 1,124,364,262.39 at the end of 2020[32] - Inventory decreased to CNY 486,041,915.73 from CNY 625,250,916.84, a reduction of approximately 22.3%[37] Investment and Other Income - Investment income for Q1 2021 was RMB 1,699,415.30, a significant increase from RMB -1,665,484.39 in the same period last year, primarily due to increased investment income from joint ventures[16] - Other income for Q1 2021 was CNY 5,812,444.68, a decrease of 44.88% from the previous year, primarily due to reduced government subsidies received[15] - The company reported an investment income of CNY 1,699,415.30, a significant recovery from a loss of CNY 1,665,484.39 in the previous year[45] Research and Development - Research and development expenses amounted to CNY 77,494,772.47, up from CNY 74,898,770.72, indicating a growth of 3.92% year-over-year[1] Earnings and Profitability - The basic earnings per share for Q1 2021 were CNY 0.16, compared to CNY 0.14 in the same quarter last year, reflecting a 14.29% increase[43] - The gross profit margin improved to 23.73% in Q1 2021, compared to 24.38% in Q1 2020[1] - The total operating costs for Q1 2021 were CNY 1,645,192,254.65, slightly higher than CNY 1,598,810,056.97 in Q1 2020[1] - Other comprehensive income after tax was CNY 790,288.84, a recovery from a loss of CNY 43,485,988.58 in the previous year[43]